PCSK9 inhibitors preferences and shared decision making

Background and Aims: High risk patients who do not reach LDL-C target currently have three options: 1) addition of PCSK9 monoclonal antibody (mAb), 2) addition of a PCSK9 siRNA, or 3) no additional medication. Shared decision making is considered important in contemporary patient care. The first step is to gain insight in the preferences of patients and healthcare providers, which is the aim of our study.

Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: J. Mulder, K. Redekop, A. Galema-Boers, L. Kranenburg, J. Roeters Van Lennep Source Type: research